

115432, г. Москва, 2й Кожуховский проезд, д. 29, корп. 2, стр. 18 тел. (499) 9732181

INDEPENDENT AUDITOR'S REPORT on the financial (accounting) statements for the period 01.01.2019-18.03.2019 Lupin Pharma, LLC

For the executive Body, for shareholders

Company: Lupin Pharma, LLC

Location & Postal address:

Nauchny Proezd, 17, office XXXIV, rooms 1-14 Moscow, 117246 Russia

OGRN: 1167746155686

Opinion

We have audited the accompanying financial statement of Lupin Pharma, LLC which comprise the liquidating balance for the period January 01, 2019 - March 18, 2019, and the notes to the liquidating balance.

In our opinion, the financial statements of Lupin Pharma, LLC for the period January 01, 2019 - March 18, 2019 are prepared in all material respects in accordance with accounting Standards of Russian Federation.

Management responsibility

Management is responsible for the preparation and fair presentation of these financial statements in according with Financial Reporting Standards of Russian Federation and for such internal control as management determines is necessary to enable the preparation of financial statement that are free from material misstatement, weather free of fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on this special purpose financial information based on our audit. We conducted our audit in accordance with Financial Reporting Standards of Russian Federation. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the special purpose financial information is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the special purpose financial information. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the special purpose financial information, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and presentation of the special purpose financial information in order to design audit

procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates, made by management, as well as evaluating the overall presentation of the special purpose financial information.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. The conclusions reached in forming our opinion are based on the component materiality level specified by you in the context of the audit of the consolidated financial statements of the group.

General Director

Chudnovskaya M.N.

Auditors Qualification Certificate № 021177

Member of the Auditors Bar of the Russian Federation
Inclusion in the list auditors 21706047685

LLC Consulting and Auditing Firm KOMVICK 99, OGRN 1147748137327, 20y Kozhukhovsky proezd, 29, k.2 p. Moscow, 115432 Member of Sodruzhestvo, the self-regulatory organization of auditors Association ORNZ 11506014448

April 05, 2019 Moscow

Прошито, пронумеровано и скреплено печатью долиста Генеральный директор ООО КАФ «КОМВИК 99»

М.Н.Чудновская



Liquidation balance as per 18 March 2018

| | | Ko | ды |
|---|--------------------------|-------|---------------|
| | Форма по ОКУД | 071 | 0001 |
| Организация Lupin Pharma LLC | Дата (число, месяц, год) | 18 (| 3 2019 |
| Идентификационный номер налогоплательщика Вид экономической | по ОКПО ИНН | | 5742 |
| деятельности Wholesale sales of pharmaceutical products Организационно-правовая форма / форма собственности | по Оквэд | 46.4 | 30511 16.1 |
| Jnits of measurement: thousand rubles | по ОКОПФ / ОКФС | 12300 | 16 |
| Address 17246, Moscow, Nauchny proyezd, 17, room XXXIV | по ОКЕИ | 38 | 4 |

| Тояснения | Parameter name | Code | As per 18 | As per 31 | As per 31 |
|-----------|---|------|------------|---------------|---|
| | ASSETS | | March 2019 | December 2018 | December 201 |
| | | | | | December 201 |
| | I. FIXED ASSETS | | | | |
| | Intangible assets | 1110 | | | |
| | | 1120 | | - | allogical is recoved a Come the registration of the |
| | | 1130 | | - | |
| | Final Control of the | 1140 | - | - | |
| | Fixed assets | 1150 | - | - | |
| | | | - | - | 4 |
| | | 1160 | | | |
| - 1 | Deferred tax assets | 1170 | - | - | |
| | Other fixed assets | 1180 | - | - | |
| - | Total section I | 1190 | | - | 4 97 |
| | | 1100 | | - | |
| 1 | II. CURRENT ASSETS nventories | 4040 | - | | 5 016 |
| | | 1210 | | | 32 152 |
| | /AT on acquired assets | 1220 | | | 02 102 |
| | accounts receivable | 1230 | - | | 2 908 |
| | | 1230 | - | - | 15 723 |
| | hort-term financial investments | 1240 | _ | | |
| M | Ionetary resources | 1250 | | - | |
| | ther current assets | 4000 | 259 | 270 | 8 195 |
| | otal part II | 1260 | - | - | 508 |
| B | alance | 1200 | 259 | 270 | |
| | | 1600 | 259 | 270 | 59 486 64 502 |

| Пояснения | Parameter name | Code | As per 18 March 2019 | As per 31 December 2018 | As per 31 December 2017 |
|-----------|--|------|-------------------------|----------------------------|----------------------------|
| | LIABILITIES | | | | |
| | III. EQUITY & RESERVES | | | | |
| | Charter capital | 1310 | 100 | 100 | 100 |
| | | 1320 | | | |
| | | 1340 | | | |
| | Additional capital | 1350 | 33 106 | 33 106 | 33 106 |
| | Reserve capital | 1360 | | - | 00 100 |
| | Undistributed earnings | 1370 | (32 947) | (32 936) | (20 046) |
| | Total for section III | 1300 | 259 | 270 | 13 159 |
| | IV. LONG-TERM LIABILITIES Loans & credits | 1410 | _ | | |
| | Deferred tax liabilities | 1420 | - | - | 9 |
| | Reserves | 1430 | - | | |
| | Other long-term liabilities | 1450 | - | - | - |
| | Total section IV | 1400 | - | - | 9 |
| | V. SHORT-TERM LIABILITIES Loans & credits | 1510 | _ | | |
| | Accounts payable | 1520 | - | _ | 50 839 |
| | Revenue to be recognized in future periods | 1530 | | - | |
| | Provisions | 1540 | - | - | 495 |
| | Other short-term liabilities | 1550 | - | - | - 100 |
| | Total for section V | 1500 | - | - | 51 334 |
| | БАЛАНС | 1700 | 259 | 270 | 64 502 |

Director,

Darya Viktorovna Chaikina (signatory)

18 March 28793

Balance sheet as per 31 March 2018

| | | | Коды |
|---|--------------------------|-------|---------|
| | Форма по ОКУД | 07 | 710001 |
| Организация Lupin Pharma LLC | Дата (число, месяц, год) | 18 | 03 2019 |
| Идентификационный номер налогоплательщика | по ОКПО | 53 | 815742 |
| вид экономической | HHN | 772 | 8330511 |
| деятельности Wholesale sales of pharmaceutical products Организационно-правовая форма / форма собственности | ло ОКВЭД | 46 | 6.46.1 |
| Limited Liability Company / Private owned Units of measurement: thousand rubles | по ОКОПФ / ОКФС | 12300 | 16 |
| Address | по ОКЕИ | | 384 |
| 117246, Moscow, Nauchny proyezd, 17, room XXXIV | - | | |

| Пояснения | Parameter name | Code | As per 31 | As per 31 | As per 31 |
|-----------|----------------------------------|------|------------|---------------|---------------|
| | ASSETS | | March 2019 | December 2018 | December 2017 |
| | | | | | 2011 |
| | I. FIXED ASSETS | | | | |
| | Intangible assets | 1110 | | | |
| | | 1120 | | - | |
| | | 1130 | | - | |
| | F: | 1140 | - | - | |
| | Fixed assets | 1150 | | - | |
| | | 1160 | _ | - | 44 |
| | | 1170 | - | | seesaa maasaa |
| | Deferred tax assets | 1180 | - | | |
| | Other fixed assets | 1190 | - | - | 4 972 |
| | Total section I | 1100 | - | - | |
| | II. CURRENT ASSETS | 1100 | - | - | 5 016 |
| | Inventories | 1210 | | | |
| | VAT on acquired assets | 1220 | | | 32 152 |
| / | Accounts receivable | 1230 | | | 2 908 |
| 1 | | 1230 | | | 15 723 |
| | Short-term financial investments | 1240 | | | 10 120 |
| | Monetary resources | 1250 | | | _ |
| | Other current assets | | 8 | 270 | 8 195 |
| | otal part II | 1260 | | _ | 508 |
| E | Balance | 1200 | 8 | 270 | 59 486 |
| | | 1600 | 8 | 270 | 64 502 |

| Пояснения | Parameter name | Code | As per 31 March 2019 | As per 31 December 2018 | As per 31 December 2017 |
|-----------|--|------|-------------------------|----------------------------|----------------------------|
| | LIABILITIES | | | | |
| | III. EQUITY & RESERVES | | | | |
| | Charter capital | 1310 | 100 | 100 | 100 |
| | | 1320 | | | |
| | | 1340 | | - | |
| | Additional capital | 1350 | 33 106 | 33 106 | 33 106 |
| | Reserve capital | 1360 | - | - | |
| | Undistributed earnings | 1370 | (33 198) | (32 936) | (20 046 |
| | Total for section III | 1300 | 8 | 270 | 13 159 |
| | IV. LONG-TERM LIABILITIES Loans & credits | 1410 | | | |
| | Deferred tax liabilities | 1420 | | | |
| | Reserves | 1430 | - | - | |
| | Other long-term liabilities | 1450 | - | - | |
| | Total section IV | 1400 | - | - | |
| | V. SHORT-TERM LIABILITIES Loans & credits | 1510 | - | | |
| | Accounts payable | 1520 | - | - | 50 839 |
| | Revenue to be recognized in future periods | 1530 | - | - | |
| | Provisions | 1540 | - | - | 49 |
| | Other short-term liabilities | 1550 | - | - | |
| | Total for section V | 1500 | - | • | 51 33 |
| | БАЛАНС | 1700 | 8 | 270 | 64 502 |



Profit and loss statement as per 31 March 2018

| | | | Коды |
|--|--------------------------|-------|---------|
| | Форма по ОКУД | 07 | 710001 |
| Организация Lupin Pharma LLC | Дата (число, месяц, год) | | 03 201 |
| Адентификационный номер налогоплательщика | по ОКПО | 53 | 815742 |
| 2014 SYCHOMNAGCKON | ИНН | | 8330511 |
| деятельности Wholesale sales of pharmaceutical products Организационно-правовая форма / форма собственности | по ОКВЭД | | 6.46.1 |
| Inited Liability Company / Private owned Inits of measurement: thousand rubles | по ОКОПФ / ОКФС | 12300 | 16 |
| ddress 17246, Moscow, Nauchny proyezd, 17, room XXXIV | по ОКЕИ | | 384 |

| Пояснения | Revenue | Code | for period January-March 2019 | for period January-March 2018 |
|-----------|---|--|-------------------------------------|--|
| | Cost of sales | 2110 | 0 | THE RESIDENCE OF THE PARTY OF T |
| | Gross profit (loss) | 2120 | 0 | 27 19 |
| | Commercial expenses | 2100 | 0 | -28 15 |
| | Overhead expenses | 2210 | 0 | -95 |
| | Profit (loss) from sales | 2220 | 0 | -1: |
| | Income from podicing to | 2200 | | -6 95 |
| | Income from participation in other entities Interest receivable | 2310 | 0 | -7 92 |
| | Interest payable | 2320 | 0 | |
| | Other income | 2330 | 0 | (|
| | Other expenses | 2340 | 0 | (|
| | Profit (loss) has | 2350 | 67 | 188 |
| | Profit (loss) before taxation | 2300 | -79 | -13 714 |
| | Current profit tax | 2410 | -12 | -21 455 |
| | ncluding permanent tax liabilities (assets) | 2421 | 0 | 0 |
| 1 | orializes in deterred tax liabilities | 2430 | 0 | 0 |
| | manges in deferred tax assets | | 0 | 0 |
| | Other | 2450 2460 | 0 | 0 |
| | Bross profit (loss) | The same of the sa | 0 | 0 |
| | | 2400 | -12 | -21 455 |

| Пояснения | - Parameter name | Code | for period January-March 2019 | for period January-March 2018 |
|-----------|--|------|-------------------------------------|-------------------------------------|
| | Income or expenses resulting from revaluation of non-current assets, that haven't been included in the net profit (loss) of the reporting period | 2510 | 0 | o |
| | Income or expenses resulting from other transactions, that haven't been included in the net profit (loss) of the reporting period | 2520 | 0 | 0 |
| | Combined financial result for the reporting period | 2500 | -12 | -21 455 |
| | For information (gross profit (loss) per share | 2900 | . 0 | 0 |
| | Diluted earnings (loss) per share | 2910 | 0 | 0 |

Director

Darya Viktorovna Chaikina (signatory)

31 March 2019

OTBL

«ANOR»

LIMITED IN

COMMAN

ABS

APOCKE AN

APOCK